Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

545 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phosphorylated vimentin as an immunotherapeutic target against metastatic colorectal cancer.
Ohara M, Ohara K, Kumai T, Ohkuri T, Nagato T, Hirata-Nozaki Y, Kosaka A, Nagata M, Hayashi R, Harabuchi S, Yajima Y, Oikawa K, Harabuchi Y, Sumi Y, Furukawa H, Kobayashi H. Ohara M, et al. Among authors: oikawa k. Cancer Immunol Immunother. 2020 Jun;69(6):989-999. doi: 10.1007/s00262-020-02524-9. Epub 2020 Feb 21. Cancer Immunol Immunother. 2020. PMID: 32086539 Free PMC article.
Intratumoral administration of cGAMP transiently accumulates potent macrophages for anti-tumor immunity at a mouse tumor site.
Ohkuri T, Kosaka A, Ishibashi K, Kumai T, Hirata Y, Ohara K, Nagato T, Oikawa K, Aoki N, Harabuchi Y, Celis E, Kobayashi H. Ohkuri T, et al. Among authors: oikawa k. Cancer Immunol Immunother. 2017 Jun;66(6):705-716. doi: 10.1007/s00262-017-1975-1. Epub 2017 Feb 27. Cancer Immunol Immunother. 2017. PMID: 28243692 Free PMC article.
Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy.
Nagato T, Ohkuri T, Ohara K, Hirata Y, Kishibe K, Komabayashi Y, Ueda S, Takahara M, Kumai T, Ishibashi K, Kosaka A, Aoki N, Oikawa K, Uno Y, Akiyama N, Sado M, Takei H, Celis E, Harabuchi Y, Kobayashi H. Nagato T, et al. Among authors: oikawa k. Cancer Immunol Immunother. 2017 Jul;66(7):877-890. doi: 10.1007/s00262-017-1987-x. Epub 2017 Mar 27. Cancer Immunol Immunother. 2017. PMID: 28349165 Free PMC article.
PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
Hirata-Nozaki Y, Ohkuri T, Ohara K, Kumai T, Nagata M, Harabuchi S, Kosaka A, Nagato T, Ishibashi K, Oikawa K, Aoki N, Ohara M, Harabuchi Y, Uno Y, Takei H, Celis E, Kobayashi H. Hirata-Nozaki Y, et al. Among authors: oikawa k. J Transl Med. 2019 Jun 20;17(1):207. doi: 10.1186/s12967-019-1957-5. J Transl Med. 2019. PMID: 31221178 Free PMC article.
A critical role of STING-triggered tumor-migrating neutrophils for anti-tumor effect of intratumoral cGAMP treatment.
Nagata M, Kosaka A, Yajima Y, Yasuda S, Ohara M, Ohara K, Harabuchi S, Hayashi R, Funakoshi H, Ueda J, Kumai T, Nagato T, Oikawa K, Harabuchi Y, Esteban C, Ohkuri T, Kobayashi H. Nagata M, et al. Among authors: oikawa k. Cancer Immunol Immunother. 2021 Aug;70(8):2301-2312. doi: 10.1007/s00262-021-02864-0. Epub 2021 Jan 28. Cancer Immunol Immunother. 2021. PMID: 33507344 Free PMC article.
A stealth antigen SPESP1, which is epigenetically silenced in tumors, is a suitable target for cancer immunotherapy.
Kosaka A, Yajima Y, Hatayama M, Ikuta K, Sasaki T, Hirai N, Yasuda S, Nagata M, Hayashi R, Harabuchi S, Ohara K, Ohara M, Kumai T, Ishibashi K, Hirata-Nozaki Y, Nagato T, Oikawa K, Harabuchi Y, Celis E, Okumura T, Ohsaki Y, Kobayashi H, Ohkuri T. Kosaka A, et al. Among authors: oikawa k. Cancer Sci. 2021 Jul;112(7):2705-2713. doi: 10.1111/cas.14973. Epub 2021 Jun 3. Cancer Sci. 2021. PMID: 34009705 Free PMC article.
545 results